Not available
Quote | Zymeworks Inc. (NYSE:ZYME)
Last: | $6.43 |
---|---|
Change Percent: | 0.47% |
Open: | $6.39 |
Close: | $6.43 |
High: | $6.6 |
Low: | $6.23 |
Volume: | 1,007,698 |
Last Trade Date Time: | 12/15/2022 03:41:52 pm |
News | Zymeworks Inc. (NYSE:ZYME)
2024-04-18 15:06:45 ET Summary Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company's flagship drug, Zanidatamab, is in phase 3 clinical trials and has significant market potential for biliary tr...
2024-04-18 13:26:38 ET Summary Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav, which has replaced Xyrem as the top treatment for narcolepsy. The company's narcolepsy franchise is facing competition from Avadel Pharmaceuticals' Lumryz, but Jazz is defend...
Message Board Posts | Zymeworks Inc. (NYSE:ZYME)
Subject | By | Source | When |
---|---|---|---|
50 million complete...... 325 million potential by the | Brokemillwright | investorshub | 11/30/2022 11:36:11 PM |
All the pumpers run away? Can't believe this | Brokemillwright | investorshub | 10/21/2022 1:53:28 AM |
Its been holding up nicely here! Lets | Clean | investorshub | 06/01/2022 1:53:11 PM |
I believe it does still look promising my friend. | DTGoody | investorshub | 05/27/2022 4:27:47 PM |
Howdy $ZYMEers. The future still looks pretty good here, | budgetthis | investorshub | 05/27/2022 3:30:25 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-04-15 22:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing ...
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manag...